For a better user experience please update your browser or use Chrome or Firefox browser.
Verktyg
Publication detail
HomeStudy of the mapping of pharmaceutical manufacturers in Korea for the Health Emergency Preparedness and Response Authority (HERA)
Publikationens metadata
This analytical study provides a comprehensive overview of the pharmaceutical manufacturing landscape in South Korea, covering generics, vaccines, diagnostics, APIs, and PPE. The data is drawn from a total of 653 registered Korean pharmaceutical companies, with a focus on major players distinguished by their revenue. Detailed company profiles and product listings are available in Annexes. South Korea's pharmaceutical market, which grew by 16.7% in 2022 to USD 22.4 billion, is a robust and expanding sector. This growth reflects an increase in both imports and exports, with domestic production standing at USD 21.7 billion, 37.3% of which is exported. Korea is a notable player in the global pharmaceutical industry, ranking as the world’s fifth-largest clinical trial market and a leader in biosimilars. Since 2019, the country has been included on the EU Whitelist, underscoring its growing international influence. The Korean pharmaceutical sector is characterized by world-class biopharmaceutical production facilities, driven by government-led initiatives, and a burgeoning presence in overseas investments.
- Utgiven:
- Författare: Health Emergency Preparedness and Response Authority (Europeiska kommissionen) , ICF
- Ämnen: Asien , Läkemedels- och kosmetikaindustri
- Ämne: clinical trial , industrial manufacturing , investment , pharmaceutical industry , pharmaceutical legislation , research and development , South Korea , supply chain , trading operation
|
PDF
|
|||
| ISSN | ISBN 978-92-9413-008-2 | DOI 10.2929/8773674 | Katalognummer LN-01-24-001-EN-N |
- Released on EU publications website:
Läsa ett dokument
Note:
Publikationen kan inte visas här. Gå till webbversionen
Här får du tillgång till publikationen: Hämta och språk